Total Payments
$66,887
2024 Payments
$66,521
Companies
14
Transactions
41
Payment Breakdown by Category
Research$64,175 (95.9%)
Travel$2,031 (3.0%)
Food & Beverage$681.38 (1.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $64,175 | 2 | 95.9% |
| Travel and Lodging | $2,031 | 8 | 3.0% |
| Food and Beverage | $681.38 | 31 | 1.0% |
Payments by Type
Research
$64,175
2 transactions
General
$2,712
39 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $66,521 | 17 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $48.21 | 4 | $0 (2020) |
| AbbVie Inc. | $47.37 | 2 | $0 (2020) |
| Astellas Pharma US Inc | $36.18 | 2 | $0 (2020) |
| Amarin Pharma Inc. | $30.39 | 2 | $0 (2020) |
| Lilly USA, LLC | $29.17 | 2 | $0 (2020) |
| Kowa Pharmaceuticals America, Inc. | $28.63 | 2 | $0 (2019) |
| Novo Nordisk Inc | $28.04 | 2 | $0 (2020) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $27.46 | 2 | $0 (2019) |
| ITI, Inc. | $25.60 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $66,521 | 17 | Eli Lilly and Company ($66,521) |
| 2021 | $25.60 | 1 | ITI, Inc. ($25.60) |
| 2020 | $99.06 | 6 | AbbVie Inc. ($24.72) |
| 2019 | $203.62 | 14 | Merck Sharp & Dohme Corporation ($36.56) |
| 2018 | $37.41 | 3 | Sunovion Pharmaceuticals Inc. ($25.29) |
All Payment Transactions
41 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $56,937.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $7,238.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $339.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $320.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $118.73 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.79 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $51.01 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $42.98 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $32.96 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $32.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $15.00 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 06/17/2024 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $14.12 | General |
| 06/16/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $891.50 | General |
| 06/16/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $208.67 | General |
| 06/16/2024 | Eli Lilly and Company | — | Travel and Lodging | In-kind items and services | $181.35 | General |
| 04/28/2021 | ITI, Inc. | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $25.60 | General |
| Category: PSYCHIATRY | ||||||
| 09/23/2020 | Astellas Pharma US Inc | MYRBETRIQ (Drug) | Food and Beverage | In-kind items and services | $18.58 | General |
| Category: UROLOGY | ||||||
| 03/11/2020 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $14.73 | General |
| Category: Cardiovascular | ||||||
| 02/17/2020 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: Diabetes | ||||||
| 02/04/2020 | Novo Nordisk Inc | Saxenda (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Obesity | ||||||
| 01/28/2020 | AbbVie Inc. | SYNTHROID (Drug) | Food and Beverage | In-kind items and services | $24.72 | General |
| Category: IMMUNOLOGY | ||||||
| 01/14/2020 | Merck Sharp & Dohme Corporation | JANUVIA (Drug), ASMANEX, BELSOMRA | Food and Beverage | In-kind items and services | $11.65 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/24/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug), XIFAXAN | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: GASTROENTEROLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $56,937 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $7,238 | 1 |
About Dr. Stephen Litman, MD
Dr. Stephen Litman, MD is a Internal Medicine healthcare provider based in Dresher, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2005. The National Provider Identifier (NPI) number assigned to this provider is 1033115134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Litman, MD has received a total of $66,887 in payments from pharmaceutical and medical device companies, with $66,521 received in 2024. These payments were reported across 41 transactions from 14 companies. The most common payment nature is "" ($64,175).
Ad
Practice Information
- Specialty Internal Medicine
- Location Dresher, PA
- Active Since 06/23/2005
- Last Updated 11/22/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1033115134
Products in Payments
- JANUVIA (Drug) $48.21
- MYRBETRIQ (Drug) $36.18
- Vascepa (Drug) $30.39
- TRULICITY (Drug) $29.17
- Livalo (Drug) $28.63
- CAPLYTA (Drug) $25.60
- APTIOM (Drug) $25.29
- SYNTHROID (Drug) $24.72
- Synthroid (Drug) $22.65
- Edarbyclor (Drug) $15.74
- TRULANCE (Drug) $14.97
- Saxenda (Drug) $14.44
- Ozempic (Drug) $13.60
- XIFAXAN (Drug) $12.49
- SHINGRIX (Biological) $12.12
- INVOKANA (Drug) $11.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.